Lorcaserin: The new miracle obesity drug that isn’t
Drug manufacturers Merck and Sanofi-Aventi both discontinued obesity drugs last year after clinical trials showed a host of psychiatric problems, ranging from depression, anxiety and suicidal thoughts. But that didn’t keep Arena Pharmaceuticals from searching for the elusive pill of thinness. The company said this week that its experimental drug to treat obesity, lorcaserin, had “succeeded” in its first late-stage clinical trial, producing results it said would be good enough for regulatory approval.
Before you get your hopes up, let’s first consider the company’s definition of “success.” According to the New York Times:
About 47.5 percent of the patients who took lorcaserin lost at least 5 percent of their weight after one year, compared with 20.3 percent of the patients who received a placebo. That is enough to satisfy the F.D.A. requirements for approval.
But the average weight loss for those taking the drug was 12.7 pounds, or 5.8 percent of body weight, compared with 4.7 pounds, or 2.2 percent for those in the placebo group. The difference between the two groups — 3.6 percent — is lower than the 5 percent requirement of the F.D.A.
Yes, that’s right. Adjusting for the placebo, study participants lost just 3.6 percent of their body weight. And that’s combined with a “moderate diet and exercise program” included in this phase of the study! For a 200-lb person, that’s just 7 pounds in one year; a 300-lb person would see just a 10 pound weight loss in one year — and again, that’s after taking lorcaserin combined with dieting and exercising! That “success” rate is less than the placebo-adjusted weight loss for Meridia, — known as Reductil overseas — a drug already on the market (although it’s been suspended in Italy and Abbott, its manufacturer, is facing scores of lawsuits for both the drug’s side effects and ineffectiveness) and is also no better than what can be achieved through traditional dieting, although it would probably make the extravagantly high costs of NutriSystem and Jenny Craig look like chump change. Meridia, for example, costs about $90 a month, has a very minimal success rate and is often not covered by prescription drug plans.
It doesn’t take a brain surgeon to see that one of the primary reasons why lorcaserin and other diet drugs like it don’t work is because they are myopic in scope. Lorcaserin, Accomplia, and taranbant work in different ways — Taranbant and Accomplia sought to block the same pleasure centers that give marijuana smokers the “munchies,” while lorcaserin stimulates a receptor in the brain that is thought to regulate food intake — but all drugs focus on appetite suppression, suggesting an assumption that fat people are fat because they eat too much, presumably unhealthy foods. This is despite the fact that researchers have identified more than 250 genetic markers for obesity and have concluded that these factors account for at least 67 percent of why one is fat. Focusing solely on appetite suppression is about as likely to “cure” obesity as is amputating a leg when what’s really needed is a hip replacement.
Lorcaserin isn’t a “promising investigative oral treatment for obesity” as touted by the company. At best, it might make obese people only infinitesimally less obese. The only arena in which it appears as if lorcaserin would be effective is in slenderizing a fat wallet.








posted on March 31st, 2009 at 11:21 am
posted on March 31st, 2009 at 11:46 am
posted on March 31st, 2009 at 11:55 am
posted on March 31st, 2009 at 12:54 pm
posted on March 31st, 2009 at 1:18 pm
posted on March 31st, 2009 at 4:33 pm
posted on April 1st, 2009 at 3:39 am
posted on June 2nd, 2009 at 10:59 am
posted on August 6th, 2009 at 11:18 am
posted on August 6th, 2009 at 12:22 pm
posted on August 6th, 2009 at 12:39 pm
posted on August 6th, 2009 at 1:03 pm
posted on August 6th, 2009 at 1:09 pm
posted on August 6th, 2009 at 2:07 pm
posted on September 30th, 2009 at 4:26 pm
posted on October 26th, 2009 at 10:54 pm
posted on December 22nd, 2009 at 7:46 pm
posted on December 23rd, 2009 at 3:01 pm
posted on May 5th, 2010 at 7:46 pm